Human innate immunity employs cellular and humoral mechanisms to facilitate rapid killing of invading bacteria. The direct killing of bacteria by human serum is attributed mainly to the activity of the complement system, which forms pores in Gram-negative bacteria. Although Gram-positive bacteria are considered resistant to killing by serum, we uncover here that normal human serum effectively kills Comparison of a well-characterized collection of commensal and clinical isolates revealed that human serum specifically kills commensal strains isolated from normal gut microbiota but not clinical isolates. Inhibitor studies show that the human group IIA secreted phospholipase A2 (hGIIA), but not complement, is responsible for killing of commensal strains in human normal serum. This is remarkable since the hGIIA concentration in "noninflamed" serum was considered too low to be bactericidal against Gram-positive bacteria. Mechanistic studies showed that serum hGIIA specifically causes permeabilization of commensal membranes. Altogether, we find that a normal concentration of hGIIA in serum effectively kills commensal and that resistance of clinical to hGIIA could have contributed to the ability of these strains to become opportunistic pathogens in hospitalized patients.
26Human innate immunity employs cellular and humoral mechanisms to facilitate rapid 27 killing of invading bacteria. The direct killing of bacteria by human serum is mainly 28 attributed to the activity of the complement system that forms pores in Gram-negative 29 bacteria. Although Gram-positive bacteria are considered resistant to serum killing, 30 we here uncover that normal human serum effectively kills Enterococcus faecium. 31 Comparison of a well-characterized collection of commensal and clinical E. faecium 32 isolates revealed that human serum specifically kills commensal E. faecium strains 33 isolated from normal gut microbiota, but not clinical isolates. Inhibitor studies show 34 that the human group IIA secreted phospholipase A2 (hGIIA), but not complement, is 35 responsible for killing of commensal E. faecium strains in human normal serum. This 36 is remarkable since hGIIA concentrations in 'non-inflamed' serum were considered 37 too low to be bactericidal against Gram-positive bacteria. Mechanistic studies showed 38 that serum hGIIA specifically causes permeabilization of commensal E. faecium 39 membranes. Altogether, we find that a normal serum concentration of hGIIA 40 effectively kills commensal E. faecium and that hGIIA resistance of clinical E. 41 faecium could have contributed to the ability of these strains to become opportunistic 42 pathogens in hospitalized patients. 43 44 Importance 45 Human normal serum contains antimicrobial components that effective kill invading 46 Gram-negative bacteria. Although Gram-positive bacteria are generally considered 47 resistant to serum killing, here we show that normal human effectively kills the Gram-48 positive Enterococcus faecium strains that live as commensals in the gut of humans. 49 In contrast, clinical E. faecium strains that are responsible for opportunistic infections 50 3 in debilitated patients are resistant against human serum. The key factor in serum 51 responsible for killing is group IIA secreted phospholipase A2 (hGIIA) that 52 effectively destabilizes commensal E. faecium membranes. We believe that hGIIA 53 resistance by clinical E. faecium could have contributed to the ability of these strains 54 to cause opportunistic infections in hospitalized patients. Altogether, understanding 55 mechanisms of immune defense and bacterial resistance could aid in further 56 development of novel anti-infective strategies against medically important multidrug 57 resistant Gram-positive pathogens. 58 59
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with đź’™ for researchers
Part of the Research Solutions Family.